Triple Combination Formulation for Treatment of Chronic Pain
AssigneesNorthwestern University, University of Notre Dame du Lac
InventorsA. Vania Apkarian, Kasturi Haldar, Suhail Alam, Maria Virginia Centeno
Life of this patent
Estimating the term…
Abstract
The disclosure relates to use of a triple formulation comprising a histone deacytlase, a cyclodextrin and polyethylene glycol or propylene glycol, and in the treatment and management of chronic pain.
Claims24
A method of treating chronic pain in a subject in need thereof, the method comprising administering to the subject a composition comprising (i) a histone deacetylase (HDAC) inhibitor, (ii) a cyclodextrin or salt thereof, and (iii) polyethylene glycol (PEG) or propylene glycol, wherein the composition is provided in a therapeutically effective amount to treat the chronic pain.
A method of reducing or inhibiting one or more symptoms of chronic pain, the method comprising administering to the subject a composition comprising (i) a histone deacetylase (HDAC) inhibitor, (ii) a cyclodextrin or salt thereof, and (iii) polyethylene glycol (PEG) or propylene glycol, wherein the composition is provided in a therapeutically effective amount to reduce or inhibit one or more symptom of chronic pain.
Use of a composition comprising (i) a histone deacetylase (HDAC) inhibitor, (ii) a cyclodextrin or salt thereof, and (iii) polyethylene glycol (PEG) or propylene glycol for manufacture of a medicament for the treatment of chronic pain or inhibition of symptoms of chronic pain.
Dependencies are inferred from the claim text.